• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

度普利尤单抗治疗细胞毒性T淋巴细胞抗原4功能不全所致严重皮肤病的疗效：2型炎症起了什么作用？

Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation?

作者信息

Arruda L Karla, Cordeiro Daniel L, Langer Sarah S, Koenigham-Santos Marcel, Calado Rodrigo T, Dias Marina M, Anhesini Leonardo R, Oliveira João Bosco, Grimbacher Bodo, Ferriani Mariana P L

机构信息

Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

出版信息

J Allergy Clin Immunol Glob. 2022 Sep 22;2(1):114-117. doi: 10.1016/j.jacig.2022.08.004. eCollection 2023 Feb.

DOI:10.1016/j.jacig.2022.08.004
PMID:37780100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509893/
Abstract

We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency.

摘要

我们报告了用度普利尤单抗成功治疗由CTLA-4功能不全引起的严重、顽固性皮炎的病例，这增加了2型免疫在与CTLA-4功能不全相关的临床病症中发挥作用的可能性。

相似文献

1
Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation?度普利尤单抗治疗细胞毒性T淋巴细胞抗原4功能不全所致严重皮肤病的疗效：2型炎症起了什么作用？
J Allergy Clin Immunol Glob. 2022 Sep 22;2(1):114-117. doi: 10.1016/j.jacig.2022.08.004. eCollection 2023 Feb.
2
Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency.比较LRBA缺陷患者和CTLA-4功能不全患者中CTLA-4依赖性生物学缺陷的水平。
Allergy. 2022 Oct;77(10):3108-3123. doi: 10.1111/all.15331. Epub 2022 May 12.
3
The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.阿巴西普临床试验方案：皮下注射阿巴西普治疗CTLA-4功能不全或LRBA缺陷患者的安全性和有效性：一项非对照2期临床试验。
Contemp Clin Trials Commun. 2022 Sep 24;30:101008. doi: 10.1016/j.conctc.2022.101008. eCollection 2022 Dec.
4
Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.度普利尤单抗治疗中重度特应性皮炎患者对循环 T 细胞功能的早期和长期影响。
J Invest Dermatol. 2021 Aug;141(8):1943-1953.e13. doi: 10.1016/j.jid.2021.01.022. Epub 2021 Feb 18.
5
Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.细胞毒性 T 淋巴细胞相关抗原 4-免疫球蛋白（CTLA-4-Ig）抑制金黄色葡萄球菌诱导的人 B 细胞中 CD80、CD86 和促炎细胞因子的表达。
Arthritis Res Ther. 2020 Mar 30;22(1):64. doi: 10.1186/s13075-020-2138-x.
6
CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis.CTLA-4 功能不全，源于新型 CTLA-4 缺失，通过拷贝数变异分析鉴定。
Int Arch Allergy Immunol. 2023;184(1):76-84. doi: 10.1159/000527051. Epub 2022 Oct 21.
7
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
8
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里，接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。
Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.
9
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
10
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.细胞毒性T淋巴细胞相关抗原4阻断与CD25(+)调节性T细胞耗竭在抗肿瘤治疗中的协同作用揭示了抑制自身反应性细胞毒性T淋巴细胞反应的替代途径。
J Exp Med. 2001 Sep 17;194(6):823-32. doi: 10.1084/jem.194.6.823.

引用本文的文献

1
Severe atopic dermatitis treated with Dupilumab in a CTLA-4-deficient patient: A case report and review of the literature.在一名CTLA-4缺陷患者中使用度普利尤单抗治疗重度特应性皮炎：病例报告及文献复习
SAGE Open Med Case Rep. 2025 Jan 7;13:2050313X241311042. doi: 10.1177/2050313X241311042. eCollection 2025.
2
Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.解析癌症免疫治疗中的调节性T细胞动态：机制、意义及治疗创新
ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2215-2236. doi: 10.1021/acsptsci.4c00156. eCollection 2024 Aug 9.

本文引用的文献

1
Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.免疫检查点缺陷与自身免疫性淋巴增生综合征。
Biomed J. 2021 Aug;44(4):400-411. doi: 10.1016/j.bj.2021.04.005. Epub 2021 Apr 19.
2
Cytotoxic T-Lymphocyte Antigen-4 Haploinsufficiency Cutaneous Manifestations.
JAMA Dermatol. 2021 Sep 1;157(9):1127-1128. doi: 10.1001/jamadermatol.2021.2317.
3
Therapeutic options for CTLA-4 insufficiency.CTLA-4 不足的治疗选择。
J Allergy Clin Immunol. 2022 Feb;149(2):736-746. doi: 10.1016/j.jaci.2021.04.039. Epub 2021 Jun 7.
4
Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council.特应性皮炎的生物标志物——国际特应性皮炎理事会综述。
J Allergy Clin Immunol. 2021 Apr;147(4):1174-1190.e1. doi: 10.1016/j.jaci.2021.01.013. Epub 2021 Jan 28.
5
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供长达 3 年的良好安全性和持续疗效。
Am J Clin Dermatol. 2020 Aug;21(4):567-577. doi: 10.1007/s40257-020-00527-x.
6
Increased Risk for Malignancies in 131 Affected Mutation Carriers.131 突变携带者恶性肿瘤风险增加。
Front Immunol. 2018 Sep 10;9:2012. doi: 10.3389/fimmu.2018.02012. eCollection 2018.
7
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.133 例细胞毒性 T 淋巴细胞抗原 4 不足个体的表型、外显率和治疗。
J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946. doi: 10.1016/j.jaci.2018.02.055. Epub 2018 May 4.
8
Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).低血清 IgE 是常见变异性免疫缺陷（CVID）的敏感且特异的标志物。
J Clin Immunol. 2018 Apr;38(3):225-233. doi: 10.1007/s10875-018-0476-0. Epub 2018 Feb 17.
9
Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines.由于 2 型细胞因子导致 CTLA4 不足引发炎症性肿瘤发生。
J Exp Med. 2018 Mar 5;215(3):841-858. doi: 10.1084/jem.20171971. Epub 2018 Jan 26.